Tyrosine-Protein Kinase JAK1 & JAK2 (JAK1 & JAK2)

Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) are intracellular, non-receptor tyrosine kinases essential for the signaling of numerous cytokines and growth factors through the JAK/STAT pathway. Both are composed of kinase and regulatory pseudokinase domains that enable signal transduction crucial for immune regulation, cell growth, differentiation, and survival. JAK1 is primarily associated with type I and II cytokine receptor signaling, strongly influencing immune cell function and inflammatory processes; JAK2 is critical in hematopoiesis and is a key mediator for receptors such as erythropoietin, thrombopoietin, and growth hormone. Dysregulation or mutation of these kinases—most notably the JAK2 V617F mutation—is implicated in cancers such as myeloproliferative neoplasms and in various autoimmune and inflammatory diseases, making them powerful therapeutic targets[2][3][4][5][1][7][6].

Other names

Janus kinase 1JAK-1Tyrosine-protein kinase JAK1Janus kinase 2JAK-2Tyrosine-protein kinase JAK2

Inhibition of kinase activity: drugs bind the kinase domain, competitively blocking ATP and thus phosphorylation of STAT substrates and downstream cytokine signaling Suppression of pro-inflammatory cytokine signaling (reducing immune cell proliferation and inflammatory mediator release) Prevention of abnormal cell growth/proliferation in myeloproliferative neoplasms and some cancers